首页> 外文学位 >Kidney segmentat ion and image analysis in autosomal dominant polycystic kidney disease
【24h】

Kidney segmentat ion and image analysis in autosomal dominant polycystic kidney disease

机译:常染色体显性遗传性多囊性肾脏疾病的肾脏分割和图像分析

获取原文
获取原文并翻译 | 示例

摘要

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is among the most prevalent life-threatening genetic conditions. Despite this, no approved medical therapies exist to treat the disease. Until the recent past, no methods could reliably measure the course of the disease far in advance of end stage renal disease (ESRD). As normal tissue is progressively destroyed or blocked by enlarging cysts, remaining nephrons compensate in a process called hyperfiltration. This beneficial physiological response confounds tests of renal function. Thus, potential interventions could not be tested against a reliable measurement of disease progression.;However, progressive changes are visually apparent on medical imaging examinations throughout the course of ADPKD. The search for ADPKD proxy biomarkers is now focused on quantitative imaging, or the extraction of information from medical images for purposes of diagnosis or disease tracking. Recent studies from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)- sponsored Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) showed Total Kidney Volume (TKV) is a usable quantitative imaging biomarker which can track disease in the early, asymptomatic phase and register measurable changes in as little as 12 months. These findings launched several new trials into potential ADPKD therapies.;Advanced analysis of polycystic kidney images, however, has never been done. The method CRISP used to extract TKV was stereology, an efficient means to estimate volume. However, stereology was tradi- tionally a dead end for further advanced analysis. TKV is useful for clinical trials and large population-based studies, but cannot accurately predict disease progression or stratify risk due to known out- lier cases. Thus, the utility of TKV for individual patient prognosis is limited. This work builds upon stereology data, describing a reliable and accurate new semi-automatic method to fully segment images us- ing only labeled stereology grids. Then, two new second generation quantitative imaging biomarkers are introduced and analyzed: Cyst- Parenchyma Surface Area (CPSA) and cyst concentration. These new physiologically motivated biomarkers will complement or potentially replace TKV in efforts to bring quantitative imaging to individual patients.;The goal of this body of work is to enable a pathway for efficient advanced image analysis in ADPKD, never before attempted in this dis- order, and to define new quantitative imaging biomarkers which will complement or replace existing ones in hopes of making individualized disease tracking for ADPKD patients a reality.
机译:常染色体显性多囊肾病(ADPKD)是最普遍的威胁生命的遗传疾病。尽管如此,尚无批准的药物可治疗该疾病。直到最近,没有任何方法能够可靠地在终末期肾病(ESRD)之前就已经对病程进行了可靠的测量。随着正常组织逐渐被囊肿破坏或阻塞,剩余的肾单位在称为超滤的过程中得到补偿。这种有益的生理反应混淆了肾功能的测试。因此,潜在的干预措施无法针对疾病进展的可靠测量进行测试。;但是,在整个ADPKD的过程中,医学影像学检查中的进行性改变在视觉上是显而易见的。现在寻找ADPKD代理生物标记的重点是定量成像或从医学图像中提取信息以进行诊断或疾病跟踪。国立糖尿病与消化与肾脏疾病研究所(NIDDK)赞助的多囊肾疾病影像学研究联盟(CRISP)最近的研究表明,总肾脏体积(TKV)是一种可用的定量成像生物标记物,可以在早期追踪疾病,无症状阶段并在短短12个月内记录可测量的变化。这些发现为潜在的ADPKD治疗方法展开了几项新的试验。然而,从未对多囊肾图像进行高级分析。 CRISP用于提取TKV的方法是立体学,这是一种估算体积的有效方法。然而,立体学传统上对于进一步的高级分析来说是死胡同。 TKV可用于临床试验和大量人群研究,但由于已知异常病例,无法准确预测疾病进展或分层风险。因此,TKV在个体患者预后中的应用受到限制。这项工作建立在立体数据之上,描述了一种可靠且准确的新型半自动方法,仅使用标记的立体网格就可以完全分割图像。然后,介绍并分析了两个新的第二代定量成像生物标记物:囊肿实质表面积(CPSA)和囊肿浓度。这些新的具有生理动机的生物标记物将补充或潜在地替代TKV,以为个体患者带来定量成像。;该工作的目标是为ADPKD中的有效的高级图像分析提供一种途径,而这一疾病之前从未尝试过,并定义新的定量成像生物标记物,以补充或替代现有的生物标记物,以期实现针对ADPKD患者的个体化疾病追踪。

著录项

  • 作者

    Warner, Joshua Dale.;

  • 作者单位

    College of Medicine - Mayo Clinic.;

  • 授予单位 College of Medicine - Mayo Clinic.;
  • 学科 Medical imaging.;Medicine.;Computer science.
  • 学位 Ph.D.
  • 年度 2016
  • 页码 267 p.
  • 总页数 267
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号